Open Access 01-12-2015 | Research
High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group
Published in: Journal of Hematology & Oncology | Issue 1/2015
Login to get access